FR2884423A1 - Utilisation de la lecithine comme medicament dans le traitement du psoriasis - Google Patents

Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Info

Publication number
FR2884423A1
FR2884423A1 FR0506496A FR0506496A FR2884423A1 FR 2884423 A1 FR2884423 A1 FR 2884423A1 FR 0506496 A FR0506496 A FR 0506496A FR 0506496 A FR0506496 A FR 0506496A FR 2884423 A1 FR2884423 A1 FR 2884423A1
Authority
FR
France
Prior art keywords
lecithin
psoriasis
treatment
medicinal product
marine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
FR0506496A
Other languages
English (en)
Other versions
FR2884423B1 (fr
Inventor
Paul Dupont
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DICOPHAR SOC CIV ILE
Original Assignee
DICOPHAR SOC CIV ILE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0506496A priority Critical patent/FR2884423B1/fr
Application filed by DICOPHAR SOC CIV ILE filed Critical DICOPHAR SOC CIV ILE
Priority to PCT/FR2006/000792 priority patent/WO2006111633A2/fr
Priority to DE602006019842T priority patent/DE602006019842D1/de
Priority to PL06743672T priority patent/PL1871399T3/pl
Priority to US11/911,743 priority patent/US7759325B2/en
Priority to EP06743672A priority patent/EP1871399B1/fr
Priority to AT06743672T priority patent/ATE496628T1/de
Priority to CA2606255A priority patent/CA2606255C/fr
Publication of FR2884423A1 publication Critical patent/FR2884423A1/fr
Application granted granted Critical
Publication of FR2884423B1 publication Critical patent/FR2884423B1/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/02—Algae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/688—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols both hydroxy compounds having nitrogen atoms, e.g. sphingomyelins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56—Materials from animals other than mammals
    • A61K35/60—Fish, e.g. seahorses; Fish eggs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Abstract

La présente invention se rapporte à l'emploi de la lécithine ou d'un extrait riche en lécithine pour la préparation d'une composition pharmaceutique utile dans la prévention et le traitement thérapeutique des dermatoses récentes ou anciennes, notamment du psoriasis. Les compositions thérapeutiques comprenant de la lécithine ou d'un extrait riche en lécithine sont également objet de la présente invention.Selon une caractéristique avantageuse de la présente invention, les phospholipides composant la lécithine sont estérifiés par des acides gras polyinsaturés du type oméga3, en particulier par l'acide docosahexanoïque (DHA), l'acide eicosapentanoïque (EPA), l'acide docosapentanoïque (DPA) ou par un alkyl-glycérol.La lécithine peut être une "lécithine marine" c'est-à-dire qu'elle est extraite d'un organisme marin choisi parmi les poissons, les crevettes, le krill, le zooplancton, les algues, le phytoplancton ou d'un mélange de ceux-ci, dont l'avantage réside dans le fait que ses phospholipides, notamment la phosphatidylcholine, sont naturellement estérifiés par des acides gras de type oméga3, et essentiellement par le DHA et l'EPA.
FR0506496A 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis Active FR2884423B1 (fr)

Priority Applications (8)

Application Number Priority Date Filing Date Title
FR0506496A FR2884423B1 (fr) 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis
DE602006019842T DE602006019842D1 (de) 2005-04-18 2006-04-11 Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
PL06743672T PL1871399T3 (pl) 2005-04-18 2006-04-11 Zastosowanie lecytyny jako leku w leczeniu łuszczycy
US11/911,743 US7759325B2 (en) 2005-04-18 2006-04-11 Use of lecithin as a medication for the treatment of psoriasis
PCT/FR2006/000792 WO2006111633A2 (fr) 2005-04-18 2006-04-11 Utilisation de la lecithine comme medicament dans le traitement du psoriasis
EP06743672A EP1871399B1 (fr) 2005-04-18 2006-04-11 Utilisation de la lecithine comme medicament dans le traitement du psoriasis
AT06743672T ATE496628T1 (de) 2005-04-18 2006-04-11 Verwendung von lecithin als arzneimittel zur behandlung von psoriasis
CA2606255A CA2606255C (fr) 2005-04-18 2006-04-11 Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0503827A FR2884425B3 (fr) 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis
FR0506496A FR2884423B1 (fr) 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Publications (2)

Publication Number Publication Date
FR2884423A1 true FR2884423A1 (fr) 2006-10-20
FR2884423B1 FR2884423B1 (fr) 2007-06-22

Family

ID=35463696

Family Applications (2)

Application Number Title Priority Date Filing Date
FR0503827A Expired - Lifetime FR2884425B3 (fr) 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis
FR0506496A Active FR2884423B1 (fr) 2005-04-18 2005-06-27 Utilisation de la lecithine comme medicament dans le traitement du psoriasis

Family Applications Before (1)

Application Number Title Priority Date Filing Date
FR0503827A Expired - Lifetime FR2884425B3 (fr) 2005-04-18 2005-04-18 Composition pharmaceutique destinee a soigner le psoriasis

Country Status (4)

Country Link
AT (1) ATE496628T1 (fr)
DE (1) DE602006019842D1 (fr)
ES (1) ES2359987T3 (fr)
FR (2) FR2884425B3 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113995763A (zh) * 2021-11-10 2022-02-01 中南大学湘雅医院 磷脂酰乙醇胺作为活性成分在制备银屑病治疗药物中的应用、银屑病治疗药物及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108004016A (zh) * 2017-12-18 2018-05-08 青岛康境海洋生物科技有限公司 一种高卵磷脂含量的南极磷虾油的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042348A1 (fr) * 1997-03-25 1998-10-01 Wilson Trafton Crandall Composition hydratante topique et methode associee
US20020012648A1 (en) * 1998-02-06 2002-01-31 Orthoefer Frank T. High phospholipid-containing dermatological compositions
WO2005002591A1 (fr) * 2003-07-02 2005-01-13 Fouad Abdelaziz Ahmed Hassanin Traitement du psoriasis, de l'impetigo, de la teigne par lipositol, cephaline et lecithine

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998042348A1 (fr) * 1997-03-25 1998-10-01 Wilson Trafton Crandall Composition hydratante topique et methode associee
US20020012648A1 (en) * 1998-02-06 2002-01-31 Orthoefer Frank T. High phospholipid-containing dermatological compositions
WO2005002591A1 (fr) * 2003-07-02 2005-01-13 Fouad Abdelaziz Ahmed Hassanin Traitement du psoriasis, de l'impetigo, de la teigne par lipositol, cephaline et lecithine

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ESCOBAR S O ET AL: "TOPICAL FISH OIL IN PSORIASIS-A CONTROLLED AND BLIND STUDY", CLINICAL AND EXPERIMENTAL DERMATOLOGY, BLACKWELL SCIENTIFIC PUBLICATIONS, OXFORD, GB, vol. 17, no. 3, 1992, pages 159 - 162, XP009030105, ISSN: 0307-6938 *
MAYSER P ET AL: "[omega]-3 Fatty acid-based lipid infusion in patients with chronic plaque psoriasis: Results of a double-blind, randomized, placebo-controlled, multicenter trial", JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY 1998 UNITED STATES, vol. 38, no. 4, 1998, pages 539 - 547, XP002360544, ISSN: 0190-9622 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113995763A (zh) * 2021-11-10 2022-02-01 中南大学湘雅医院 磷脂酰乙醇胺作为活性成分在制备银屑病治疗药物中的应用、银屑病治疗药物及其制备方法
CN113995763B (zh) * 2021-11-10 2023-08-11 中南大学湘雅医院 磷脂酰乙醇胺作为活性成分在制备银屑病治疗药物中的应用、银屑病治疗药物及其制备方法

Also Published As

Publication number Publication date
ATE496628T1 (de) 2011-02-15
FR2884423B1 (fr) 2007-06-22
ES2359987T3 (es) 2011-05-30
DE602006019842D1 (de) 2011-03-10
FR2884425A1 (fr) 2006-10-20
FR2884425B3 (fr) 2007-05-25

Similar Documents

Publication Publication Date Title
EA200802204A1 (ru) Применение ингибиторов dpp iv
SMT201300095B (it) Uso dell'estere etilico dell'acido eicosapentaenoico per trattare l'ipertrigliceridemia
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
BR112013005673A2 (pt) uso de lipase de ácido lisossomal para tratamento de deficiência de lipase de ácido lisossomal em pacientes
EA200702204A1 (ru) Лечение заболеваний соединительной ткани кожи
RU2007101538A (ru) Применение фармацевтической композиции, содержащей кальцитриол и пропионат клобетазола, для лечения псориаза
BRPI0507622B8 (pt) composto baseado em ácido hialurônico, processo para preparar um composto ou um sal do mesmo, composição farmacêutica, produto medicinal e dispositivo médico para uso humano ou veterinário, e,uso de composto ou de um sal do mesmo
ATE525084T1 (de) Verwendung von mindestens einem botulinum- neurotoxin zur behandlung von schmerzen infolge therapeutischer behandlungen für das aids-virus
CL2007002652A1 (es) Compuestos derivados de isoserina, inhibidores del factor de coagulacion de la sangre ixa; procedimiento de preparacion; y su uso para preparar un medicamento para tratar enfermedades acompanadas de trombosis, embolias, hipercoagulabilidad o cambios
UY28209A1 (es) Derivados de aminoácidos con cicloalquilo, procedimiento para su preparación y su uso como medicamentos.
NO20075199L (no) Treatment or prevention of pruritus
FR2884423B1 (fr) Utilisation de la lecithine comme medicament dans le traitement du psoriasis
BR0116653A (pt) Medicamento contendo uma poliamina como substância ativa
TW200716192A (en) Use of adamantyl methoxydiphenyl propenoic acid for the treatment of dermatological diseases
DK2004235T3 (da) Sammensætning til kosmetisk eller farmaceutisk-dermatologisk anvendelse
PT1585513E (pt) Utilizacao de acido docosa-hexaenoico como substancia activa para o tratamento de lipodistrofia
WO2006076119A3 (fr) Traitement de dermatoses
TW200508229A (en) Cycloalkyl derivatives having bioisosteric carboxylic acid groups, processes for their preparation and their use as pharmaceuticals
TH87784B (th) สูตรเฉพาะที่มี o-เดสเมทธิลเวนลาฟาซีน(odv)หรือเกลือของมัน
MA28210A1 (fr) Composition pharmaceutique contenant en association l'ubidecarenone, le dexpanthenol et le chlorhexidine ou leurs sels acceptables du point de vue pharmaceutique pour application cutanee
HUP0600046A2 (en) Pharmaceutical composition containing folic acid and it's use
TH75095A (th) การรักษาโรคผิวหนัง
TNSN06068A1 (en) Pharmaceutical composition containing in association ubidecarenone, dexpanthenol and chlorhexidine or a pharmaceutically acceptable salt thereof for cutaneous application
BRPI0404771A (pt) medicamento e tratamento para dores em geral e outros sintomas
UA87052C2 (ru) Мазь на основе тиотриазолина для лечения раневого процесса во второй и третьей стадиях

Legal Events

Date Code Title Description
CL Concession to grant licences

Name of requester: PHYBIO PHARMA, CH

Effective date: 20130218

Name of requester: SARL PHYTOBIOLAB, FR

Effective date: 20130218

PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13

PLFP Fee payment

Year of fee payment: 14

PLFP Fee payment

Year of fee payment: 15

PLFP Fee payment

Year of fee payment: 16

PLFP Fee payment

Year of fee payment: 17

PLFP Fee payment

Year of fee payment: 18

PLFP Fee payment

Year of fee payment: 19